Role of factor V Leiden or G20210A prothrombin mutation in patients with symptomatic pulmonary embolism and deep vein thrombosis: A meta-analysis of the literature

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 4, 2012, Pages 732-737

  Dentali, F ^a   Ageno, W ^a   Bozzato, S ^a   Malato, A ^b   Gianni, M ^c   Squizzato, A ^a   Prisco, D ^d  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c Hospital of Tradate   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; PROTHROMBIN; BLOOD CLOTTING FACTOR 5;

DEEP VEIN THROMBOSIS; GENE MUTATION; HUMAN; LETTER; LUNG EMBOLISM; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PUBLISHING; RISK ASSESSMENT; SYSTEMATIC REVIEW; ADOLESCENT; ADULT; AGED; BLOOD; BLOOD CLOTTING; CHI SQUARE DISTRIBUTION; CHILD; FEMALE; GENETIC PREDISPOSITION; GENETICS; MALE; META ANALYSIS; MIDDLE AGED; MUTATION; PHENOTYPE; RISK; RISK FACTOR; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD COAGULATION; CHI-SQUARE DISTRIBUTION; CHILD; FACTOR V; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MUTATION; ODDS RATIO; PHENOTYPE; PROTHROMBIN; PULMONARY EMBOLISM; RISK ASSESSMENT; RISK FACTORS; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 84859191010     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04656.x     Document Type: Letter

References (10)

1. Emmerich J, Rosendaal FR, Cattaneo M, Margaglione M, De Stefano V, Cumming T, Arruda V, Hillarp A, Reny JL. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism - pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001; 86: 809-16.
2. McGinn T, Wyer PC, Newman TB, Keitz S, Leipzig R, For GG; for Evidence-Based Medicine Teaching Tips Working Group. Tips for learners of evidence-based medicine: 3. Measures of observer variability (kappa statistic). CMAJ 2004; 171: 1369-73.
3. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ 2001; 323: 101-5.
4. Perrier A. Deep vein thrombosis and pulmonary embolism: a single disease entity with different risk factors? Chest 2000; 118: 1234-6.
5. van 't Veer C, Kalafatis M, Bertina RM, Simioni P, Mann KG. Increased tissue factor initiates prothrombin activation as a result of the Arg506-Gln mutation in factor V Leiden. J Biol Chem 1997; 272: 20721-9.
6. Bajzar L, Kalafatis M, Simioni P, Tracy PB. An antifibrinolytic mechanism describing the prothrombotic effect associated with factor V Leiden. J Biol Chem 1996; 271: 2949-52.
7. Castoldi E, Simioni P, Tormene D, Thomassen MC, Spiezia L, Gavasso S, Rosing J. Differential effects of high prothrombin levels on thrombin generation depending on the cause of the hyperprothrombinemia. J Thromb Haemost 2007; 5: 971-9.
8. Björgell O, Nilsson PE, Nilsson JA, Svensson PJ. Location and extent of deep vein thrombosis in patients with and without FV: R506Q mutation. Thromb Haemost 2000; 83: 648-51.
9. van Stralen KJ, Doggen CJ, Bezemer ID, Pomp ER, Lisman T, Rosendaal FR. Mechanisms of the factor V Leiden paradox. Arterioscler Thromb Vasc Biol 2008; 28: 1872-7.
10. Martinelli I, Battaglioli T, Razzari C, Mannucci PM. Type and location of venous thromboembolism in patients with factor V Leiden or prothrombin G20210A and in those with no thrombophilia. J Thromb Haemost 2007; 5: 98-101.